Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | AHCY | P23526 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237360 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL29383092 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982387 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL12123492 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL1678967 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23982120 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL176347 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL8712178 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21562191 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982396 | 1.00 | PNP (0.79) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139312-A1 | Biversals in DNA Manipulation and Sequencing | BENNER STEVEN (US) | 2026-05-21 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| CN-118304256-A | Nucleoside supermolecule hydrogel for stem cell delivery and preparation method and application thereof | 四川大学 | 2024-07-09 | — | — | CN | claimed |
| US-20240182874-A1 | NOVEL FAMILY OF DNA POLYMERASES ACCEPTING 2-AMINOADENINE AND REJECTING ADENINE IN THEIR SUBSTRATES | THE EUROPEAN SYNDICATE OF SYNTHETIC SCIENTISTS AND IND (FR) | 2024-06-06 | — | — | US | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-4323511-A1 | NOVEL FAMILY OF DNA POLYMERASES ACCEPTING 2-AMINOADENINE AND REJECTING ADENINE IN THEIR SUBSTRATES | The European Syndicate of Synthetic Scientists and Industrialists (FR) | 2024-02-21 | — | — | EP | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-113980860-B | Nonomuria with high yield of prastatin and 2 '-amino-2' -deoxyadenosine and application thereof | 天津商业大学 | 2023-09-08 | — | — | CN | claimed |
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-27 | — | — | US | claimed |
| EP-2678431-A1 | OLIGONUCLEOTIDE INHIBITORS WITH CHIMERIC BACKBONE AND 2-AMINO-2'-DEOXYADENOSINE | PharmAxis Ltd (AU) | 2014-01-01 | — | — | EP | claimed |
| US-8470999-B2 | Oligonucleotides for treating inflammation and neoplastic cell proliferation | PAQUET LUC (CA) | 2013-06-25 | — | — | US | claimed |
| WO-2012113067-A1 | OLIGONUCLEOTIDE INHIBITORS WITH CHIMERIC BACKBONE AND 2-AMINO-2'-DEOXYADENOSINE | PHARMAXIS LTD (AU) | 2012-08-30 | — | — | WO | claimed |
| US-20110144183-A1 | OLIGONUCLEOTIDES FOR TREATING INFLAMMATION AND NEOPLASTIC CELL PROLIFERATION | PAQUET LUC | 2011-06-16 | — | — | US | claimed |
| US-20100286235-A1 | METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | TOPIGEN PHARMACEUTIQUE INC. (CA) | 2010-11-11 | — | — | US | claimed |
| US-7745420-B2 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | TOPIGEN PHARMACEUTIQUE, INC. (CA) | 2010-06-29 | — | — | US | claimed |
| WO-2006038865-A1 | NUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS | BETAGENON AB (SE) | 2006-04-13 | — | — | WO | claimed |
| US-5888777-A | Process for the complete removal of protective groups on nucleoside diphosphate and triphosphate sugars with acetylesterase | NOVARTIS AG (CH) | 1999-03-30 | — | — | US | claimed |
| EP-0801684-A1 | PROCESS FOR THE COMPLETE REMOVAL OF PROTECTIVE GROUPS ON NUCLEOSIDE DIPHOSPHATE AND TRIPHOSPHATE SUGARS | Novartis AG (CH) | 1997-10-22 | — | — | EP | claimed |
| WO-1996024683-A1 | PROCESS FOR THE COMPLETE REMOVAL OF PROTECTIVE GROUPS ON NUCLEOSIDE DIPHOSPHATE AND TRIPHOSPHATE SUGARS | NOVARTIS AG (CH) | 1996-08-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | PNP 23/4885LMNA 2914/4885TP53 1122/4885 |
| US-20260139312-A1 | Biversals in DNA Manipulation and Sequencing | POLRMT, RNGTT, FBL | PNP 41/4885LMNA 420/4885TP53 3725/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | PNP 688/4885LMNA 233/4885TP53 204/4885 |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | RNGTT, SPOUT1, NPEPPS | PNP 31/4885LMNA 2457/4885TP53 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.